GO:0001572 lactosylceramide biosynthetic process: Glycosphingolipid Synthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001572 describes the biosynthesis of lactosylceramide (LacCer), a disaccharide-core glycosphingolipid formed by the transfer of galactose to glucosylceramide.
• LacCer is the central branching precursor for gangliosides, globosides, and isoglobosides, making it a hub for glycosphingolipid diversity.
• The committed step is catalyzed by beta-1,4-galactosyltransferase 5 (B4GalT5), which uses UDP-galactose to modify glucosylceramide.
• LacCer-enriched lipid rafts act as signaling platforms in infection immunity and host-pathogen interactions.
• Dysregulated lactosylceramide metabolism is linked to osteoarthritis, cardiac hypertrophy, and cancer energy metabolism.
• CRISPR knockout, knock-in, and overexpression models enable causal dissection of B4GalT5, UGCG, and related genes in LacCer biology.
Description
Lactosylceramide (LacCer) is a glycosphingolipid composed of a ceramide lipid anchor linked to a disaccharide of galactose and glucose. The Gene Ontology term GO:0001572, lactosylceramide biosynthetic process, defines the chemical reactions and pathways that produce this molecule, beginning with the synthesis of the 4-Gal-beta-1,4-Glc-ceramide core. This core is not merely an end product; it is the branching point from which cells build a vast array of complex glycosphingolipids, including gangliosides, globosides, and isoglobosides. Understanding this process is therefore fundamental to lipid biology, membrane organization, and cell signaling research. LacCer is enriched in specialized membrane microdomains known as lipid rafts, where it participates in signal transduction, host-pathogen recognition, and immune responses. Its biosynthesis is tightly coupled to the upstream production of glucosylceramide by UDP-glucose ceramide glucosyltransferase (UGCG) and the subsequent action of beta-1,4-galactosyltransferase 5 (B4GalT5). Perturbations in this pathway have been observed in osteoarthritis, cardiac hypertrophy, and multiple cancers, underscoring its clinical relevance. For researchers, GO:0001572 provides a precise framework to study how cells generate and regulate LacCer. By combining CRISPR-based genetic models with lipidomics, imaging, and biochemical assays, it is now possible to dissect the causal roles of individual enzymes and transport proteins in this pathway. This article synthesizes authoritative GO annotations and verified literature to guide experimental design and interpretation.
lactosylceramide biosynthetic process At A Glance
| GO ID | GO:0001572 |
|---|---|
| GO term | lactosylceramide biosynthetic process |
| Ontology | biological_process |
| Synonym | lactosylceramide biosynthesis; lactosylceramide synthesis; lacto-series glycosphingolipid biosynthesis |
| Major function | Synthesis of the disaccharide-core glycosphingolipid lactosylceramide, a precursor for complex glycosphingolipids |
| Key enzyme | B4GalT5 (beta-1,4-galactosyltransferase 5) |
| Upstream precursor | Glucosylceramide, synthesized by UGCG |
| Subcellular location | Golgi apparatus membrane |
| Related pathways | Ganglioside biosynthesis, globoside biosynthesis, isogloboside biosynthesis |
What Is GO:0001572?
GO:0001572, lactosylceramide biosynthetic process, is the biological process encompassing the chemical reactions and pathways that result in the formation of lactosylceramides. The process begins with the synthesis of a disaccharide core, 4-Gal-beta-1,4-Glc-ceramide, from glucosylceramide and a galactose donor. This core can be further elongated by the sequential addition of various carbohydrate units, and it also serves as the precursor for the synthesis of gangliosides, globosides, and isoglobosides.
Why Is lactosylceramide biosynthetic process Important in Cell Biology?
Lactosylceramide biosynthesis is a central metabolic node because it generates the precursor for a large family of bioactive glycosphingolipids that modulate membrane structure, cell signaling, and immune recognition. LacCer-enriched lipid rafts serve as platforms for pathogen binding and immune cell activation, and alterations in this pathway are associated with osteoarthritis, cardiac hypertrophy, and cancer metabolic reprogramming. Consequently, understanding GO:0001572 is essential for researchers in lipid biology, immunology, and metabolic disease.
• Provides the disaccharide core for gangliosides, globosides, and isoglobosides, which are critical for neuronal and immune cell function.
• LacCer-enriched lipid rafts mediate host-pathogen interactions and infection immunity.
• Dysregulation of lactosylceramide synthesis is observed in osteoarthritis articular cartilage.
• UGCG and B4GalT5, key enzymes in the pathway, modulate cardiac hypertrophy through mitochondrial oxidative stress and ERK signaling.
• Glycosphingolipids, including LacCer, influence cancer cell energy metabolism and proliferation.
• Glycolipid transfer proteins regulate the intracellular trafficking of LacCer and related lipids.
• LacCer biosynthesis is a potential therapeutic target for metabolic and inflammatory diseases.
• CRISPR-based models allow precise dissection of gene function in this pathway.
• Lipidomics and molecular dynamics simulations provide complementary tools to study LacCer metabolism.
• Host LacCer can enhance infection by pathogens such as Edwardsiella tarda.
What Happens During lactosylceramide biosynthetic process?
Synthesis of glucosylceramide: the upstream precursor
In simple terms: First, the cell builds a simple lipid-sugar molecule called glucosylceramide.
The lactosylceramide biosynthetic process begins with the formation of glucosylceramide, which is synthesized by the enzyme UDP-glucose ceramide glucosyltransferase (UGCG). UGCG transfers glucose from UDP-glucose to ceramide, creating the monohexosylceramide that serves as the substrate for the next step. This reaction occurs on the cytosolic face of the Golgi apparatus, and the product is subsequently translocated to the lumenal side for further processing.
Galactose transfer by B4GalT5: the committed step
In simple terms: Next, an enzyme adds a galactose sugar to glucosylceramide, forming lactosylceramide.
The committed step in lactosylceramide biosynthesis is catalyzed by beta-1,4-galactosyltransferase 5 (B4GalT5), which transfers galactose from UDP-galactose to glucosylceramide, forming the 4-Gal-beta-1,4-Glc-ceramide core. This reaction takes place in the Golgi lumen and is essential for the production of lactosylceramide and all downstream glycosphingolipids. B4GalT5 is a type II membrane protein, and its activity is influenced by the availability of UDP-galactose and the lipid environment.
Formation of the disaccharide core and its branching potential
In simple terms: The resulting lactosylceramide can be decorated with more sugars to make many different complex lipids.
Once formed, lactosylceramide serves as the central branching precursor for the synthesis of gangliosides, globosides, and isoglobosides. The disaccharide core can be elongated by sequential addition of carbohydrate units, including sialic acid, N-acetylgalactosamine, and fucose, through the action of specific glycosyltransferases. This branching diversity is critical for the functional specialization of glycosphingolipids in different cell types and tissues.
Intracellular trafficking and lipid raft association
In simple terms: Lactosylceramide is transported within the cell and clusters in specialized membrane regions.
After synthesis, lactosylceramide is transported from the Golgi to the plasma membrane, where it becomes enriched in lipid rafts, which are cholesterol- and sphingolipid-rich microdomains. Glycolipid transfer proteins facilitate the non-vesicular transport of lactosylceramide and other glycolipids between membranes, contributing to its distribution and function. Molecular dynamics simulations have been used to study the behavior of glycolipids in liposomes, providing insights into their membrane organization.
Regulation of lactosylceramide biosynthesis
In simple terms: The cell controls how much lactosylceramide is made by adjusting enzyme levels and substrate supply.
The lactosylceramide biosynthetic process is regulated at multiple levels, including the expression and activity of UGCG and B4GalT5, the availability of UDP-glucose and UDP-galactose, and the intracellular trafficking of ceramide and glycolipids. UGCG modulates cardiac hypertrophy through B4GalT5-mediated mitochondrial oxidative stress and ERK signaling, indicating that this pathway is integrated with cellular stress responses. Additionally, glycosphingolipid levels can influence cancer cell energy metabolism, suggesting feedback regulation between lipid synthesis and metabolic state.
Key Genes Involved in GO:0001572 lactosylceramide biosynthetic process
The following genes and proteins are directly involved in or closely associated with the lactosylceramide biosynthetic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| B4GalT5 | Beta-1,4-galactosyltransferase 5; transfers galactose to glucosylceramide to form lactosylceramide | Key enzyme for LacCer synthesis; knockout reduces LacCer and downstream glycosphingolipids |
| UGCG | UDP-glucose ceramide glucosyltransferase; synthesizes glucosylceramide, the precursor of LacCer | Upstream regulator; modulates cardiac hypertrophy and oxidative stress |
| GLTP | Glycolipid transfer protein; facilitates non-vesicular transport of glycolipids | Regulates intracellular distribution of LacCer and other glycolipids |
| CERT | Ceramide transfer protein; transports ceramide from ER to Golgi | Indirectly affects substrate availability for LacCer synthesis |
| ST3GAL5 | GM3 synthase; converts LacCer to ganglioside GM3 | Downstream enzyme; determines ganglioside synthesis |
| B3GALT4 | Beta-1,3-galactosyltransferase 4; elongates LacCer to globosides | Downstream branching enzyme |
| A4GALT | Alpha-1,4-galactosyltransferase; synthesizes isoglobosides from LacCer | Downstream branching enzyme |
| B4GALNT1 | Beta-1,4-N-acetyl-galactosaminyltransferase 1; synthesizes GM2/GD2 | Downstream ganglioside synthesis |
| HEXA | Beta-hexosaminidase A; degrades GM2 ganglioside | Lysosomal enzyme; mutations cause Tay-Sachs disease |
| HEXB | Beta-hexosaminidase B; degrades globosides | Lysosomal enzyme; mutations cause Sandhoff disease |
| GBA | Glucocerebrosidase; degrades glucosylceramide | Lysosomal enzyme; mutations cause Gaucher disease |
| SMPD1 | Acid sphingomyelinase; hydrolyzes sphingomyelin to ceramide | Affects ceramide supply for LacCer synthesis |
| ERK1/2 | Mitogen-activated protein kinases; signaling downstream of LacCer | Mediates B4GalT5-dependent cardiac hypertrophy |
| TLR4 | Toll-like receptor 4; recognizes lipid raft components | LacCer-enriched rafts modulate TLR4 signaling |
| CD1d | Antigen-presenting molecule for glycolipids | Presents glycosphingolipids to NKT cells |
| LAMP1 | Lysosomal-associated membrane protein 1 | Marker for lysosomal glycolipid degradation |
How Is lactosylceramide biosynthetic process Regulated?
The lactosylceramide biosynthetic process is regulated by the expression and activity of UGCG and B4GalT5, as well as by substrate availability and intracellular trafficking. UGCG modulates cardiac hypertrophy through B4GalT5-mediated mitochondrial oxidative stress and the ERK signaling pathway, indicating that this biosynthetic route is integrated with stress-responsive kinase cascades. Glycosphingolipid levels can also influence cancer cell energy metabolism, suggesting crosstalk between lipid synthesis and metabolic reprogramming. Additionally, glycolipid transfer proteins such as GLTP regulate the distribution of lactosylceramide between membranes, indirectly affecting its availability for downstream reactions.
lactosylceramide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B4GalT5 | Cardiac hypertrophy; oxidative stress | Cardiomyocyte-specific knockout or overexpression in mice |
| UGCG | Cardiac hypertrophy; glycosphingolipid storage | UGCG knockout or knockdown in cell lines and animal models |
| B4GalT5 | Osteoarthritis; cartilage lipid changes | Chondrocyte-specific knockout or lipidomics in cartilage explants |
| GLTP | Glycolipid trafficking; potential neurological disorders | GLTP knockout or tagged knock-in for live-cell imaging |
| ST3GAL5 | Ganglioside biosynthesis; cancer metabolism | ST3GAL5 knockout or overexpression in cancer cell lines |
Lactosylceramide in osteoarthritis
Lipidomic profiling of osteoarthritis articular cartilage has revealed significant changes in lipid composition, including glycosphingolipids such as lactosylceramide. These alterations suggest that dysregulated lactosylceramide biosynthesis may contribute to cartilage degradation and joint inflammation. Targeting the enzymes involved in this pathway could offer new therapeutic strategies for osteoarthritis.
Cardiac hypertrophy and oxidative stress
UGCG, the enzyme that produces glucosylceramide, modulates heart hypertrophy through B4GalT5-mediated mitochondrial oxidative stress and the ERK signaling pathway. This indicates that lactosylceramide biosynthesis is mechanistically linked to cardiac stress responses, and that manipulating this pathway could influence hypertrophic remodeling.
Cancer metabolism and glycosphingolipids
Glycosphingolipids, including lactosylceramide and its downstream products, influence cancer cell energy metabolism. Alterations in lactosylceramide biosynthesis can affect membrane signaling, proliferation, and metabolic flexibility, making this pathway a potential target for cancer therapy.
Infection immunity and host-pathogen interactions
Lactosylceramide-enriched lipid rafts play a role in infection immunity, serving as platforms for pathogen recognition and immune signaling. Host lactosylceramide can enhance infection by Edwardsiella tarda, demonstrating that this glycosphingolipid directly influences host-pathogen interactions.
From lactosylceramide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does B4GalT5 loss reduce lactosylceramide levels? | B4GalT5 knockout cell line (e.g., HEK293 or HeLa) |
| Does a point mutation in B4GalT5 alter enzyme activity? | Point-mutation knock-in via CRISPR in a cell line |
| Can tagged B4GalT5 be used to track Golgi localization? | Knock-in of fluorescent or epitope tag at the endogenous B4GalT5 locus |
| Does UGCG overexpression increase LacCer and downstream gangliosides? | UGCG overexpression stable cell line |
| How does GLTP regulate LacCer trafficking? | GLTP knockout or overexpression with lipid imaging |
| What is the role of LacCer in pathogen infection? | Host cell knockout of B4GalT5 followed by Edwardsiella tarda infection |
How to Study the lactosylceramide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Quantification of lactosylceramide and other lipids | Profiling disease tissues and knockout cell lines |
| Molecular dynamics simulation | Behavior of glycolipids in lipid bilayers | Studying LacCer raft formation |
| Glycolipid transfer assay | Rate of glycolipid transfer between membranes | Characterizing GLTP function |
| CRISPR knockout | Loss-of-function effects on LacCer synthesis | Validating B4GalT5 and UGCG as key enzymes |
| CRISPR knock-in | Tagged or mutant protein expression | Tracking B4GalT5 localization and activity |
| Overexpression | Gain-of-function effects on pathway flux | Increasing LacCer and downstream products |
| Immunofluorescence | Subcellular localization of enzymes and lipids | Visualizing Golgi and lipid raft association |
| Infection assays | Host-pathogen interaction | Testing LacCer role in Edwardsiella tarda infection |
Lipidomics and mass spectrometry
Lipidomics using mass spectrometry allows comprehensive profiling of lactosylceramide and related glycosphingolipids in cells and tissues. This approach has been used to identify lipid changes in osteoarthritis articular cartilage, revealing alterations in lactosylceramide levels. Targeted lipidomics can quantify the effects of genetic perturbations in B4GalT5 or UGCG.
Molecular dynamics simulations
Molecular dynamics simulations of glycolipids in liposomes provide atomic-level insights into the behavior of lactosylceramide in membranes. These simulations help researchers understand how LacCer interacts with cholesterol and other lipids to form lipid rafts.
Glycolipid transfer assays
Glycolipid transfer proteins can be studied using in vitro transfer assays between donor and acceptor liposomes. These assays measure the rate of lactosylceramide transfer and help define the role of proteins such as GLTP in intracellular trafficking.
CRISPR-based genetic screens
CRISPR knockout screens can identify genes required for lactosylceramide biosynthesis and its downstream effects. By targeting B4GalT5, UGCG, and related glycosyltransferases, researchers can systematically dissect the pathway and its contribution to disease phenotypes.
How CRISPR Can Be Used to Study GO:0001572 lactosylceramide biosynthetic process
Knockout
CRISPR knockout of B4GalT5 or UGCG eliminates lactosylceramide biosynthesis, providing a clean genetic model to study downstream effects on glycosphingolipid composition and cell signaling. Knockout cell lines can be analyzed by lipidomics to confirm the loss of LacCer and its derivatives.
Point Mutation
Point mutations in B4GalT5 can be introduced via CRISPR to dissect catalytic residues or regulatory sites, allowing researchers to separate enzyme activity from protein interactions. Such models are valuable for understanding how specific mutations affect lactosylceramide synthesis and disease phenotypes.
Knock-in
Knock-in of fluorescent or epitope tags at the endogenous B4GalT5 locus enables live-cell imaging of the enzyme's Golgi localization and trafficking. Tagged knock-in models can also be used to study the dynamics of lactosylceramide biosynthesis in real time.
Overexpression
Overexpression of B4GalT5 or UGCG increases lactosylceramide production and can be used to study gain-of-function effects on cell proliferation, metabolism, and disease models. Overexpression models are particularly useful for testing whether increased LacCer synthesis is sufficient to drive phenotypes such as cardiac hypertrophy or cancer metabolic reprogramming.
How EDITGENE Supports lactosylceramide biosynthetic process Research
Researchers studying lactosylceramide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in LacCer synthesis, trafficking, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes such as B4GalT5, UGCG, and GLTP.
Contact EDITGENE today to design your custom CRISPR model for lactosylceramide biosynthetic process research.
Frequently Asked Questions About lactosylceramide biosynthetic process
What is lactosylceramide biosynthetic process?
Lactosylceramide biosynthetic process (GO:0001572) is the biological pathway that produces lactosylceramide, a glycosphingolipid with a 4-Gal-beta-1,4-Glc-ceramide core, which serves as a precursor for gangliosides, globosides, and isoglobosides.
What genes are involved in lactosylceramide biosynthetic process?
Key genes include B4GalT5, which transfers galactose to glucosylceramide, and UGCG, which synthesizes the upstream precursor glucosylceramide. Other related genes include GLTP, ST3GAL5, and B3GALT4.
Which enzyme catalyzes the committed step in lactosylceramide synthesis?
Beta-1,4-galactosyltransferase 5 (B4GalT5) catalyzes the committed step by transferring galactose from UDP-galactose to glucosylceramide.
Where does lactosylceramide biosynthesis occur in the cell?
Lactosylceramide biosynthesis occurs in the Golgi apparatus, where glycosyltransferases such as B4GalT5 are localized.
What diseases are associated with lactosylceramide biosynthesis?
Alterations in this pathway have been linked to osteoarthritis, cardiac hypertrophy, cancer metabolism, and host-pathogen infections.
How can I study lactosylceramide biosynthesis using CRISPR?
CRISPR knockout of B4GalT5 or UGCG eliminates lactosylceramide production, while knock-in of tagged enzymes allows live-cell imaging. Overexpression models can test gain-of-function effects.
What is the role of lactosylceramide in lipid rafts?
Lactosylceramide is enriched in lipid rafts, where it participates in signal transduction and host-pathogen recognition.
Can lactosylceramide biosynthesis be measured by lipidomics?
Yes, mass spectrometry-based lipidomics can quantify lactosylceramide and related glycosphingolipids in cells and tissues.
What is the relationship between lactosylceramide and gangliosides?
Lactosylceramide is the direct precursor for ganglioside synthesis; enzymes such as ST3GAL5 convert it to GM3, the simplest ganglioside.
How does UGCG regulate lactosylceramide biosynthesis?
UGCG synthesizes glucosylceramide, the substrate for B4GalT5, and its expression modulates cardiac hypertrophy through B4GalT5-mediated oxidative stress and ERK signaling.
Conclusion
The lactosylceramide biosynthetic process (GO:0001572) is a central metabolic pathway that generates a key glycosphingolipid precursor with diverse roles in membrane organization, signaling, and disease. Its committed enzyme, B4GalT5, and upstream regulator UGCG are critical for LacCer production and downstream ganglioside and globoside synthesis. Dysregulation of this pathway is implicated in osteoarthritis, cardiac hypertrophy, cancer metabolism, and infection immunity. By leveraging CRISPR knockout, knock-in, and overexpression models combined with lipidomics and imaging, researchers can dissect the causal roles of individual genes in this pathway. EDITGENE provides end-to-end services to accelerate such studies, from model generation to bioinformatics analysis, empowering discoveries in glycosphingolipid biology and therapeutic development.
References
- 1. Zhou Q et al.. 2025. Lipidomics unravels lipid changes in osteoarthritis articular cartilage.. Ann Rheum Dis 84(7):1264-1276 PMID: 39894691
- 2. Brown RE et al.. 2007. Glycolipid transfer proteins.. Biochim Biophys Acta 1771(6):746-60 PMID: 17320476
- 3. Cui S et al.. 2023. UGCG modulates heart hypertrophy through B4GalT5-mediated mitochondrial oxidative stress and the ERK signaling pathway.. Cell Mol Biol Lett 28(1):71 PMID: 37658291
- 4. Iwabuchi K. 2018. [Lactosylceramide-enriched Lipid Raft-mediated Infection Immunity].. Med Mycol J 59(3):J51-J61 PMID: 30175814
- 5. Yasuda T et al.. 2023. Molecular Dynamics of Glycolipids in Liposomes.. Methods Mol Biol 2613:257-270 PMID: 36587084
- 6. Tuuf J et al.. 2014. Membranes and mammalian glycolipid transferring proteins.. Chem Phys Lipids 178:27-37 PMID: 24220498
- 7. Schömel N et al.. 2020. Influence of glycosphingolipids on cancer cell energy metabolism.. Prog Lipid Res 79:101050 PMID: 32592726
- 8. Oishi K et al.. 2021. Host lactosylceramide enhances Edwardsiella tarda infection.. Cell Microbiol 23(9):e13365 PMID: 33988901
